Sender Co & Partners Inc. Purchases 3,662 Shares of Zoetis Inc. $ZTS

Key Points

• Sender Co & Partners Inc. increased its shares in Zoetis Inc. by 43.1% to a total of 12,163 shares, making up 1.1% of its investment portfolio, valued at approximately $2,003,000.
• Several institutional investors, including Brighton Jones LLC and CoreCap Advisors LLC, also boosted their positions in Zoetis during the last quarter, reflecting growing confidence in the stock.
• Zoetis reported strong quarterly earnings with an EPS of $1.76, surpassing analyst expectations, and has set EPS guidance for FY 2025 between $6.300-6.400.

Sender Co & Partners Inc. raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 43.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,163 shares of the company's stock after acquiring an additional 3,662 shares during the period. Zoetis comprises approximately 1.1% of Sender Co & Partners Inc.'s holdings, making the stock its 25th largest holding. Sender Co & Partners Inc.'s holdings in Zoetis were worth $2,003,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ZTS. 1248 Management LLC bought a new position in Zoetis in the first quarter worth $27,000. Saudi Central Bank acquired a new position in shares of Zoetis in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC lifted its holdings in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after acquiring an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after acquiring an additional 120 shares during the period. Finally, Sound Income Strategies LLC boosted its position in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after acquiring an additional 164 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Price Performance

Shares of NYSE:ZTS traded down $0.34 during midday trading on Wednesday, reaching $149.45. The company's stock had a trading volume of 2,734,299 shares, compared to its average volume of 3,036,727. The business's fifty day simple moving average is $152.90 and its 200-day simple moving average is $157.61. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a market capitalization of $66.24 billion, a P/E ratio of 25.72, a P/E/G ratio of 2.44 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company's revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent research reports. Piper Sandler increased their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Argus reissued a "buy" rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.